Onco Actu du 27 juillet 2018

	3.1 Prévention - Tabac
FDA In Brief: FDA affirms commitment to warning the public about nicotine in tobacco products following court ruling [FDA] The court’s temporary hold only affects cigars and pipe tobacco, and the FDA is enforcing the requirements on other tobacco products.
	3.8 Prévention - Alimentation
Adherence to Healthy Diets Associated with Lower Cancer Risk [AACR] In order to examine links between the four nutritional indices and cancer risk, Srour, Touvier, and colleagues drew data from the NutriNet-Santé study, launched in 2009 to investigate associations between nutrition and health in a French cohort. This study included a large sample of 41,543 participants aged 40 or older, who had never been diagnosed with cancer prior to inclusion in the study.
	4.14 Dép., diag. & prono. - Thyroïde
MicroRNA Panel Can Identify Malignancy in Indeterminate Thyroid Nodules [AACR] The sensitivity, specificity, negative predictive value, positive predictive value, and overall accuracy of the diagnostic panel as compared to the gold standard pathology were 91 percent, 100 percent, 87 percent, 100 percent, and 94 percent, respectively.
	5.1 Traitements - Pré-clinique
Scientists discover a mechanism of drug resistance in breast and ovarian cancer [Rockefeller University] In BRCA1-deficient cancers treated with PARP inhibitors, the rewriting function of 53BP1 leads to faulty repair of DNA and the death of the cancerous cells. Yet some of these cells manage to escape treatment by losing 53BP1. The work from de Lange’s lab explains just how this change allows them to survive.
	5.12.5 Immunothérapies - Pharma
Bristol-Myers to get negative CHMP opinion on renal cancer drugs [Reuters] “We strongly disagree with this opinion. And in the interest of patients, we will pursue a reexamination.”
	5.12.6 Immunothérapies - AMM
KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma [Merck] KEYTRUDA Approved By China National Drug Administration (CNDA) in Five Months, Accelerating Availability of Anti-PD-1 Option to Advanced Melanoma Patients in China.
FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer [NCI] Under the change, pembrolizumab and atezolizumab should be used as an initial, or first-line, treatment in only those people with metastatic bladder cancer who can’t receive cisplatin-based chemotherapy and whose tumors have high levels of PD-L1. The assessment of PD-L1 levels must be made using an FDA-cleared test.
	5.12.8 Immunothérapies - Economie
AstraZeneca's new launches shine in Q2 as it inches toward turnaround [FiercePharma] Sales of lung cancer drug Tagrisso soared by 77% to $422 million for the quarter, while those of immuno-oncology product Imfinzi nearly doubled from last quarter’s haul. The therapy pulled in $122 million in Q2 on the back of a new lung cancer maintenance approval to record $184 million in the year’s first half.
Bristol-Myers surprise: Threatened I-O drug Opdivo stands its ground in lung cancer [FiercePharma] Bristol-Myers’ big cancer drugs helped lead the charge, with immuno-oncology star Opdivo generating a $1.63 billion haul that trounced forecasts of $1.46 billion. One reason? The drug has held its ground in the second-line lung cancer market, maintaining a leadership share of about 30% to 35%.
	5.2 Pharma
AstraZeneca Can't Boost a Cancer Drug Stockpile for Brexit [Bloomberg] The drugmaker is already making Zoladex, a drug for cancers of the prostate and breast, at full capacity, Chief Executive Officer Pascal Soriot said in an interview. That means inventory can’t be increased to four months from three, as the company is doing with other products in case of Brexit-related distribution delays.
	5.2.1 Pharma - Partenariats
23andMe Sold Access to Your DNA Library to Big Pharma, But You Can Opt Out [Motherboard] 23andMe customers can opt out of the program, but that misses the point.
	5.2.3 Pharma - économie
On top of expiring Herceptin patents, Roche faces huge royalty losses in 2019 [EndPoints] It’s a troubling problem to have considering the fact that Roche will soon be losing its exclusivity on Herceptin, whose patent expiration is also in 2019. Herceptin sales makes up a big chunk of the Roches’s total revenue, bringing in $7 billion in sales last year.
Sutro Biopharma Announces $85.4 Million Series E Round [Sutro] STRO-001 and STRO-002 were developed using Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimization of protein conjugates to treat cancer and other diseases.
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline [EndPoints] The company’s lead program is STRO-001 — in Phase I trials for lymphoma and multiple myleloma. And they have a preclinical drug, STRO-002, which they’re planning to push into human trials in early 2019. That one’s targeting ovarian and endometrial cancer.
	5.4 Traitements - Economie
NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC [ESMO] It will be available for non-squamous NSCLC through the Cancer Drugs Fund until more evidence is collected.
	6.1 Observation
Half of U.S. breast surgeons may advise unneeded lymph node removal [Reuters] Surgeons who did a higher volume of breast cancer procedures were less likely to advise women with early-stage tumors to get all axillary nodes removed, researchers report in JAMA Oncology.
	6.6 Publications
A Q&A with John Pham, the new Editor-in-Chief of Cell [CellPress] I support how Cell is already changing to move into fields like immunotherapy, genomics, and human genetics. On top of that, I would like to see more technology and technology development, because new technologies have been so instrumental to our progress.
Technology + Engagement = Infrastructure Sustainability [ORCID] How can we track progress toward achieving our mission? As of today, we have over five million users, and more than 900 members with 580 integrations.
	6.7 DMP, Big Data & applis
Powerful people in health care are finding a new landing pad: Google [STAT] The moves are a sign of Alphabet’s rise as a formidable player in health care — even as the hype and funding so far outpaces tangible accomplishments.